Morgan Stanley’s Edesa Biotech EDSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.4K | Buy |
+1,400
| New | +$12.6K | ﹤0.01% | 7005 |
|
|
2026
Q1 | – | Sell |
-2,300
| Closed | -$3.27K | – | 8347 |
|
|
2025
Q4 | $3.27K | Buy |
+2,300
| New | +$4.5K | ﹤0.01% | 7146 |
|
|
2025
Q3 | – | Sell |
-584
| Closed | -$1.19K | – | 8215 |
|
|
2025
Q2 | $1.19K | Buy |
+584
| New | +$1.24K | ﹤0.01% | 7315 |
|
|
2025
Q1 | – | Sell |
-14
| Closed | -$24 | – | 8118 |
|
|
2024
Q4 | $24 | Sell |
14
-14
| -50% | -$39 | ﹤0.01% | 7829 |
|
|
2024
Q3 | $125 | Hold |
28
| – | – | ﹤0.01% | 7414 |
|
|
2024
Q2 | $120 | Hold |
28
| – | – | ﹤0.01% | 7332 |
|
|
2024
Q1 | $117 | Hold |
28
| – | – | ﹤0.01% | 7362 |
|
|
2023
Q4 | $128 | Sell |
28
-1
| -3% | -$4 | ﹤0.01% | 7329 |
|
|
2023
Q3 | $126 | Buy |
+29
| New | +$171 | ﹤0.01% | 7426 |
|
|
2023
Q1 | – | Sell |
-196
| Closed | -$2.96K | – | 7745 |
|
|
2022
Q4 | $2.96K | Buy |
196
+26
| +15% | +$194 | ﹤0.01% | 7271 |
|
|
2022
Q3 | $1K | Hold |
170
| – | – | ﹤0.01% | 7557 |
|
|
2022
Q2 | $2K | Hold |
170
| – | – | ﹤0.01% | 7581 |
|
|
2022
Q1 | $4K | Sell |
170
-39
| -19% | -$1.08K | ﹤0.01% | 7626 |
|
|
2021
Q4 | $8K | Buy |
209
+180
| +621% | +$8.61K | ﹤0.01% | 7528 |
|
|
2021
Q3 | $1K | Buy |
+29
| New | +$1.13K | ﹤0.01% | 7767 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6596 |
|
|
2019
Q4 | – | Sell |
-838
| Closed | -$29.7K | – | 6672 |
|
|
2019
Q3 | $37K | Sell |
838
-1,638
| -66% | -$59.5K | ﹤0.01% | 5828 |
|
|
2019
Q2 | $122K | Buy |
+2,476
| New | +$109K | ﹤0.01% | 5232 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6612 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6621 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6727 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6682 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6633 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6584 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6546 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6600 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6581 |
|
|
2016
Q3 | – | Sell |
-2
| Closed | -$2K | – | 6515 |
|
|
2016
Q2 | $2K | Buy |
2
+1
| +100% | +$1.03K | ﹤0.01% | 6362 |
|
|
2016
Q1 | $1K | Buy |
+1
| New | +$1.75K | ﹤0.01% | 6464 |
|
Other funds holding EDSA
VCIM
RCMNY
PA
SCM
BCM
Morgan Stanley's EDSA Position: Q2 2026 in Review
Morgan Stanley opened a new position in Edesa Biotech (EDSA) in Q2 2026: 1,400 shares worth $11.4K. The stake represents ﹤0.01% of the portfolio and ranks #7005 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in EDSA as recently as Q4 2025.
Morgan Stanley first reported a position in EDSA in Q1 2016 and has held it in 19 quarters since. The position peaked at $122K in Q2 2019. 33 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.
- Morgan Stanley held 1,400 shares of Edesa Biotech worth $11.4K as of Q2 2026.
- Edesa Biotech was a new Morgan Stanley position in Q2 2026.
- Edesa Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7005 holding.
- Morgan Stanley first reported a position in Edesa Biotech in Q1 2016 and has held it in 19 quarters since.
- Morgan Stanley's Edesa Biotech position peaked at $122K in Q2 2019.
- 33 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.